Fibrocell Science Inc (FCSC) Upgraded to Hold at Zacks Investment Research
Fibrocell Science Inc (NASDAQ:FCSC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “
A number of other research analysts have also weighed in on FCSC. ValuEngine raised shares of Fibrocell Science from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 15th. HC Wainwright set a $6.00 price objective on shares of Fibrocell Science and gave the company a “buy” rating in a research note on Wednesday, August 9th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $7.00 price objective (up from $3.00) on shares of Fibrocell Science in a research note on Monday, September 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Fibrocell Science presently has an average rating of “Hold” and a consensus price target of $5.21.
Fibrocell Science (NASDAQ:FCSC) last issued its earnings results on Wednesday, August 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.31). Equities research analysts expect that Fibrocell Science will post ($2.17) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece was reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/10/fibrocell-science-inc-fcsc-upgraded-to-hold-at-zacks-investment-research.html.
A hedge fund recently raised its stake in Fibrocell Science stock. Parametric Portfolio Associates LLC raised its holdings in Fibrocell Science Inc (NASDAQ:FCSC) by 264.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 48,259 shares of the company’s stock after buying an additional 35,000 shares during the period. Parametric Portfolio Associates LLC owned about 0.33% of Fibrocell Science worth $194,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 54.70% of the company’s stock.
About Fibrocell Science
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.